PostEra
YC W20Boston, US · Founded 2019 · 40 employees · 4 known investors
Postera uses artificial intelligence and computational chemistry to accelerate drug discovery for pharmaceutical companies. The platform combines machine learning, medicinal chemistry, and software engineering to improve the drug development process.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesAI-powered Drug DiscoveryMachine LearningCOVID-19in /postera-ai/@PostEra_AI
Founders & leadership· Y Combinator alumni (W20)
Investors · 4
In the news
- How PostEra designs drugs from codecen.acs.org · 2026
- PostEra Secures $610M in Funding to Revolutionize Drug Discovery with Machine Learning Technology | SignalBasetrysignalbase.com · 2025
- Pfizer extends AI drug discovery pact with PostEra, adding ADCs to dealendpts.com · 2025
- Amgen lines up new AI biotech partner in PostEra – Endpoints Newsendpts.com · 2023
- NIH grants over $500M to create antivirals for future pandemics – Endpoints Newsendpts.com · 2022
- PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH fundingprnewswire.com · 2022
- A new AI startup has emerged, and Pfizer likes what it sees – Endpoints Newsendpts.com · 2022
- PostEra - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxntracxn.com · 2021